جست‌وجوی استاد و پژوهشگر

Martijn W.F. van den Hoogenمشاهده پروفایل

پژوهشگر

• Kidney Transplantation
• Transplant Immunology
• B Cell Biology
• +۱۲ مورد دیگر

Martijn W.F. van den Hoogen is a researcher at Erasmus MC in the Department of Internal Medicine, specializing in kidney transplantation and immunology. His work bridges clinical practice and translational research, with a strong focus on improving transplant outcomes through immunological insights and innovative patient care strategies. Research Interests: Dr. van den Hoogen's research spans several critical areas in transplant medicine, including kidney allograft survival , trained immunity , B-cell and T-cell responses , and immunosuppressive therapies . He also investigates telemedicine applications for post-transplant care and disparities in access to transplantation , particularly among immigrant populations in Europe. His recent work explores vascular repair mechanisms and endothelial chimerism in human vein models. The trends in his recent publications indicate a strong emphasis on clinical and immunological aspects of transplantation , combining systematic reviews , observational studies , and translational models . His work frequently addresses real-world challenges such as medication nonadherence, healthcare accessibility, and immune monitoring. Scientific Contributions: Co-authored high-impact studies in journals like American Journal of Transplantation and Transplantation . Active in both primary research and meta-analyses to synthesize evidence in transplant medicine. Engaged in multidisciplinary collaborations across immunology, nephrology, and public health. Advising and Grants: While no specific students or grants are listed in the provided text, his involvement in multiple collaborative research projects suggests active participation in research teams and likely supervision of junior researchers or fellows. His work on systematic reviews and clinical studies may be supported by institutional or national research funding, though specific grants are not mentioned. Labs and Teams: Dr. van den Hoogen is part of a robust research network at Erasmus MC, collaborating with experts in transplant immunology, nephrology, and vascular biology. His work on endothelial cell chimerism and trained immunity suggests involvement in both clinical and experimental research teams focused on improving long-term outcomes in kidney transplant recipients.

Alf Kristian Bergمشاهده پروفایل

پژوهشگر

• Photochemical Internalization (PCI)
• Photodynamic Therapy (PDT)
• Drug Delivery Systems
• +۷ مورد دیگر

Alf Kristian Berg is a researcher affiliated with the University of Oslo's Section for Galenic Pharmacy and Community Pharmacy. His work focuses on advancing drug delivery systems through photochemical internalization (PCI), photodynamic therapy (PDT), and nanomedicine. Key research areas include enhancing cancer treatment efficacy via light-activated drug delivery mechanisms, targeting cancer stem cells, and developing novel therapeutic biomaterials. His research has been published in high-impact journals such as Nature Communications , Cancers , and Frontiers in Immunology . Major contributions include demonstrating PCI's role in bypassing biological barriers (e.g., blood-brain barrier) and improving chemotherapy/gene therapy outcomes. Collaborations span institutions like the University of Manchester and the University of Leeds, emphasizing translational applications of his findings. Despite no explicitly listed awards, his extensive publication record reflects significant contributions to photomedicine and oncology. His lab's work integrates molecular biology, biophysics, and engineering to address unmet clinical needs in targeted therapies.

Elena Lomakinaمشاهده پروفایل

عضو هیئت علمی

• Cell Adhesion
• Immunology
• Biomechanics
• +۳ مورد دیگر

Elena Lomakina, M.D., Ph.D., is a Research Assistant Professor in the Department of Biomedical Engineering at the University of Rochester, School of Medicine and Dentistry. Her research focuses on cellular mechanics, cell adhesion, and the biophysical mechanisms governing leukocyte-endothelial interactions during inflammation. She holds a PhD in Cell Biology from Russian State Medical University (1995) and an MD (1992), followed by postdoctoral training at the University of Rochester (2001–2006). Her work integrates experimental and theoretical approaches to study how mechanical forces and molecular interactions regulate cell behavior. Key areas include the role of cell surface topography in adhesion, glycocalyx-mediated barrier function, and the mechanics of leukocyte migration. Collaborations with the Waugh Lab and others explore red blood cell maturation, microfluidic systems for cell culture, and the dynamics of CAR T cell migration. Lomakina’s research has led to over 25 peer-reviewed articles, including studies on integrin activation, neutrophil phagocytosis, and endothelial glycocalyx properties. Her lab employs advanced techniques like atomic force microscopy and micropipette aspiration to probe cellular mechanics. Ongoing projects investigate the impact of mechanical forces on immune cell function and the development of microfluidic platforms to model vascular inflammation.

• CAR-T Cell Therapy
• Cancer Immunotherapy
• Molecular Biology
• +۳ مورد دیگر

Dr. Veronika Bandara is a Research Fellow at the University of Adelaide's School of Biomedicine within the Faculty of Health and Medical Sciences. She holds a PhD and specializes in molecular biology and cancer immunotherapy. Her research focuses on developing CAR-T cell therapies targeting cancer markers such as LGR5, nfP2X7, and ADAM10, with a strong emphasis on translational applications for solid tumors like colorectal and ovarian cancers. She leads projects on CAR-T development, including FDA-approved clinical trials for LGR5-targeting therapies and collaborations with Carina Biotech Ltd. Research Interests: Her work bridges basic science and clinical translation, encompassing CAR-T cell engineering, preclinical validation, and GMP manufacturing protocols. Key areas include LGR5 receptor targeting for neuroblastoma and pediatric brain cancers, nfP2X7 CAR-T development for pan-cancer applications, and understanding regulatory T cell mechanisms in autoimmune diseases. Publications & Grants: Over 20 peer-reviewed articles since 2010, focusing on CAR-T efficacy, biomarker validation, and molecular mechanisms in immunology. Co-inventor of nfP2X7 CAR-T patents. Active in collaborative grants through the Cooperative Research Centre for Cell Therapy Manufacturing. Advising & Labs: Eligible to supervise Masters/PhD students as co-supervisor. Primary lab affiliation: Molecular Immunology Lab. Current projects include CAR-T translational work and autoimmune disease regulatory T cell studies. Labs/Teams: Collaborates with Carina Biotech and leads research teams at the University of Adelaide's Medical Sciences division.

• Neuro-oncology
• Genomic and epigenetic profiling
• Metabolic therapies for gliomas
• +۵ مورد دیگر

Professor Tracy Warr is a leading neuro-oncology researcher at the University of Wolverhampton's Research Institute in Healthcare Science, with over 25 years of experience in experimental brain tumour research. Previously at University College London's Institute of Neurology, she established a research programme focused on glioma treatment outcomes since 2009. Her work spans genomic/epigenetic analysis, metabolic therapies, and tumour immunosuppression. PhD, University of Wales Swansea (1991) BSc, University of Leeds (1986) Research Themes: Therapeutic target validation in paediatric/adult gliomas Metabolic dysregulation and repositioned drugs Epigenetic mechanisms in brain metastases Tumour-mediated immunosuppression in GBM Pre-clinical model development Dietary modulation of cancer progression Publication Trends: Recent work focuses on non-coding RNA methylation patterns in metastatic breast cancer, hexokinase 2's epigenetic regulation in glioblastoma, and arginine biosynthesis pathway inactivation in paediatric high-grade gliomas. Earlier studies explored PDE1C's role in tumour proliferation, flavonoid effects on invasion, and p53 dynamics in chromosomal instability. Scientific Recognition: Honorary Professor, Third Military Medical University (2012) Advising & Grants: Supervised numerous PhD projects on topics like metformin therapy, miRNA roles in angiogenesis, and secretomic analysis of GBM immunosuppression. Current research funded by grants including "Unravelling T cell immunosuppression" (Headcase Cancer Trust) and "Role of miR-133a" (Royal Wolverhampton NHS Trust).

Neil E. Kayمشاهده پروفایل

استاد

• Chronic Lymphocytic Leukemia (CLL)
• B-cell Biology
• Hematology
• +۱۲ مورد دیگر

Neil E. Kay, M.D., is a Professor of Medicine at Mayo Clinic in Rochester, Minnesota, where he serves as a Consultant in the Division of Hematology, Department of Internal Medicine, with a joint appointment in the Department of Immunology. His research is focused on chronic lymphocytic leukemia (CLL), particularly its biological and clinical heterogeneity, tumor microenvironment, B-cell signaling, and genomic evolution. Primary Appointment: Consultant, Division of Hematology, Department of Internal Medicine Joint Appointment: Consultant, Department of Immunology Academic Rank: Professor of Medicine Location: Mayo Clinic, Rochester, MN Dr. Kay has established a nationally recognized CLL tissue bank and clinical database that supports extensive translational and basic research. He collaborates with leading scientists at Mayo Clinic and beyond, including experts in immunology, pathology, epidemiology, and biostatistics. His research interests include: B-chronic lymphocytic leukemia (CLL) Tumor microenvironment and stromal interactions B-cell biology and signaling Genomic and epigenomic analysis of CLL clones Clonal evolution and risk stratification Development of novel therapies and clinical trials Recent publications reveal a strong focus on genomic characterization of CLL, particularly in underrepresented populations, mechanisms of therapy resistance, Richter transformation, and innovative approaches such as CAR-T cell modulation. His work increasingly integrates whole-genome sequencing, epidemiological data, and clinical trial outcomes to improve patient prognosis and personalize treatment. Scientific awards and leadership roles include: Member, Leukemia Steering Committee, National Cancer Institute Chairman, CLL Steering Committee, National Cancer Institute Member, Leukemia Core Committee, Eastern Cooperative Oncology Group Member, External Advisory Group (CLL), MD Anderson Cancer Center Section Editor, Leukemia Dr. Kay leads multiple active research grants from the National Cancer Institute and U.S. Army, focusing on predicting clinical outcomes and enhancing CAR-T cell safety. He has mentored numerous researchers and contributed over 500 peer-reviewed publications. His work is central to advancing understanding and treatment of CLL, with a vision toward curative strategies. He is involved in several laboratories and research programs at Mayo Clinic, including the Mayo Clinic Comprehensive Cancer Center, the Developmental Therapeutics Program, and collaborative networks such as the Eastern Cooperative Oncology Group and the CLL Working Group at the National Cancer Institute.

Jean Jaubertمشاهده پروفایل

پژوهشگر

• Laboratory Animal Science
• Animal Welfare and Ethics
• Reproductive Animal Science
• +۷ مورد دیگر

Jean Jaubert is a Permanent Researcher and Head at the Central Animal Facility of the Institut Pasteur in Paris, France. His work focuses on providing access to animal models and experimental settings in compliance with animal welfare and ethical standards. Research Interests: His expertise spans laboratory animal science, reproductive animal science, animal welfare and ethics, biosafety, risk assessment, and bioconfinement. His research supports immunological, infectious disease, and genetic studies using rodent models, particularly mice. He contributes to translational research by maintaining health status and experimental integrity in animal facilities. Publication Trends: Recent publications highlight his involvement in genetic mapping using the Collaborative Cross (CCQTL), immune cell differentiation (iNKT cells), and development of mouse-adapted pathogens like SARS-CoV-2. These works reflect an interdisciplinary focus on host-pathogen interactions, immunogenetics, and bioinformatics tools for complex trait analysis. Scientific Awards: No awards listed in the provided text. Advising and Grants: There is no explicit mention of students or direct advising roles. Funding sources are not specified in the provided text, though his platform involvement suggests participation in collaborative or institutional grants supporting animal facility operations and related research. Labs and Teams: Jean Jaubert leads the Central Animal Facility, a core platform at the Institut Pasteur. The team includes veterinarians, research engineers, project managers, and technicians, supporting a wide range of in vivo studies. The facility also offers training courses on rodent surgery and regulatory compliance for project designers.

Aleksandra Deczkowskaمشاهده پروفایل

پژوهشگر

• Neuroimmunology
• Systems Biology
• Genomics
• +۱۲ مورد دیگر

Aleksandra Deczkowska is a Researcher and Principal Investigator at the Pasteur Institute in Paris, affiliated with the Computational Structural Biology unit. She leads a dynamic research team investigating the critical interactions between the immune system and the brain, with a focus on neuroimmunology, brain aging, and neurodegenerative diseases such as Alzheimer's. Her work integrates cutting-edge genomic technologies to decode immune-brain communication in both health and disease. Her research focuses on understanding how immune cells, particularly microglia and dendritic cells, regulate brain physiology, maintenance, and development. She explores the systemic nature of diseases like Alzheimer's and investigates how peripheral immune signals influence brain function. Her lab is actively involved in projects on brain maintenance 24/7, immune-brain communication in postnatal development, and the systemic aspects of Alzheimer's disease. Dr. Deczkowska's recent publications appear in top-tier journals including Nature , Nature Medicine , Immunity , and Nature Reviews Immunology , reflecting her significant contributions to immunology and neuroscience. Her work spans neuroimmunology, systems biology, genomics, and cellular immunity, often revealing novel mechanisms of immune regulation in the central nervous system and liver. Selected Scientific Contributions: Elucidating the role of microglial plasticity in brain aging Identifying XCR1+ dendritic cells as drivers of liver inflammation in metabolic disease Revealing how NASH impairs cancer immunotherapy Characterizing immune cells in the choroid plexus Investigating meningeal immune responses in spinal cord pathologies She mentors a team of postdoctoral fellows, PhD students, and research engineers, fostering the next generation of scientists in the field of neuroimmunology. Her laboratory is at the forefront of integrating systems-level approaches to understand complex immune-brain interactions, with implications for treating neurodegenerative and metabolic diseases.

• Cell-Material Interaction
• Biomaterials
• Plasma Medicine
• +۱۲ مورد دیگر

Prof. Dr. Barbara Nebe is a faculty member at the Institute of Cell Biology, University of Rostock, where she serves as the Head of the Cell Biology Unit at University Medicine Rostock. She holds the academic rank of Associate Professor (apl. Professorin) and is actively involved in interdisciplinary research in biomaterials, cell-material interactions, and plasma medicine. Her work bridges medicine, engineering, and materials science, with a strong focus on implant biocompatibility and regenerative medicine. Academic Rank: Associate Professor Department: Institute of Cell Biology University: University of Rostock Research Focus: Cell-Material Interaction, Plasma Functionalization, Osteoblast Behavior, Biomaterials Her research interests center on how physical and chemical surface modifications of biomaterials influence cellular behavior, particularly osteoblast adhesion, differentiation, and signaling. She investigates the role of surface topography, plasma polymerization, and nanoscale features in modulating cell responses, with applications in orthopedics, dentistry, and regenerative medicine. She also explores the biological effects of phytoestrogens and plant extracts in cancer and regenerative contexts. Her recent publications demonstrate a strong trend in plasma-based surface engineering of titanium and zirconia implants, 3D scaffold design, computational modeling of nutrient transport, and antimicrobial strategies. The work spans experimental cell biology, materials characterization, and in vivo validation, showing a highly interdisciplinary approach. Key themes include osteoconductivity, anti-infective coatings, and mechanotransduction. Scientific awards received include the Joachim-Jungius-Förderpreis, multiple poster awards from the German Society for Biomaterials, and a best lecture award. She has been recognized internationally for her contributions to biomaterials and plasma medicine. She has led and participated in numerous DFG-funded projects such as GRK welisa and SPP 322, focusing on implant-biosystem interactions. She has also been active in scientific service, serving on the board of the German Society for Biomaterials (DGBM), the steering committee of Campus PlasmaMed, and as a co-organizer of major international conferences like THERMEC and E-MRS. She leads a research group focused on cellular adhesion and stem cell biology, with laboratory activities centered on advanced microscopy, surface functionalization, and 3D cell culture systems. Her team collaborates closely with materials scientists, plasma physicists, and clinicians to develop next-generation bioactive implants.

Claudia Arndtمشاهده پروفایل

پژوهشگر

• Cancer Research
• Immunotherapy
• T-Cell Engineering
• +۳ مورد دیگر

Claudia Arndt is a Researcher at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) , leading the group Engineered T-cells for personalized cancer therapy within the Department of Radioimmunology . Her work focuses on advancing cell-based immunotherapies, particularly modular, switchable chimeric antigen receptor (CAR) T-cell strategies, integrating therapeutic control, radioimmunotherapy, and in vivo imaging for personalized oncology. Research Highlights include: Developing innovative CAR T-cell platforms (e.g., UniCAR) for precise cancer targeting. Combining radioimmunotherapy with hematopoietic cell transplantation protocols to enhance treatment efficacy. Investigating therapy resistance mechanisms in blood cancers like acute myeloid leukemia (AML) and multiple myeloma. Selected Publications reflect her interdisciplinary approach, spanning in vivo imaging, T-cell engineering, and clinical validation of novel cancer therapies. Contact: c.arndt@hzdr.de | HZDR Website

Daniel Bauerمشاهده پروفایل

دانشیار

• Gene Therapy
• Genome Editing
• CRISPR-Cas9
• +۱۴ مورد دیگر

Daniel Bauer is a faculty member at Boston Children's Hospital and Dana-Farber Cancer and Blood Disorders Center, affiliated with Harvard Medical School in the Department of Hematology and Oncology. His research is centered on developing gene-editing therapies for blood disorders, particularly sickle cell disease and thalassemia. University: Boston Children's Hospital School: Harvard Medical School Department: Department of Hematology and Oncology Dr. Bauer’s research focuses on leveraging CRISPR and base editing technologies to reactivate fetal hemoglobin and correct genetic defects in hematopoietic stem cells. His work spans from mechanistic studies of hemoglobin switching regulators like BCL11A to translational applications in non-human primates and human cells. He has pioneered methods to improve editing efficiency, reduce genotoxicity, and develop safer delivery systems. His recent publications highlight a strong trend in refining gene-editing tools for clinical use—emphasizing in vivo delivery, off-target assessment, prime editing optimization, and culture-free editing to preserve stem cell function. These studies demonstrate a clear trajectory toward curative therapies for hemoglobinopathies. Dr. Bauer has mentored trainees and led a productive research program, though specific student names and awards are not listed in the provided text. He has secured research funding to support his lab’s work in genome editing and therapeutic development. He leads a research team focused on genetic medicine for blood disorders, integrating molecular biology, genomics, and preclinical models to advance gene therapy. His lab is actively involved in both basic and translational research, aiming to bridge the gap between bench discoveries and clinical applications.

• Nanomaterials Design
• Bio-inspired Smart Materials and Interfaces
• Sustainable Energy and Technology
• +۷ مورد دیگر

Professor Ziqi Sun is a leading academic in the Faculty of Science at Queensland University of Technology (QUT), where he serves in the School of Chemistry & Physics. He holds the position of Professor and is also an ARC Mid-Career Industry Fellow, reflecting his significant contributions to materials science and sustainable energy research. His work is supported by major competitive grants including ARC Discovery and Future Fellowships. Education: PhD in Engineering, Chinese Academy of Sciences, China (2009) BEng in Materials Science and Engineering, Central South University, China (2003) Professor Sun's research focuses on nanomaterials design , bio-inspired smart materials , sustainable energy technologies , and functional ceramics . His work spans the synthesis and self-assembly of metal oxide nanostructures, wettability of complex surfaces, and energy storage systems. He has pioneered advances in 2D heterostructures, bioinspired interfaces, and multifunctional coatings, with applications in photovoltaics, batteries, and electrocatalysis. His recent publications highlight a strong trend toward bioinspired design , 2D materials for energy , and advanced electrochemical systems , particularly in aqueous batteries and water splitting technologies. These works reflect interdisciplinary innovation in materials science, chemistry, and engineering for sustainability. Scientific Awards and Honors: TMS FMD Young Leaders Professional Development Award (2015) ARC DECRA Fellow (2015) ARC Future Fellow (2018) UOW Vice-Chancellor’s Research Fellowship (2013) Alexander von Humboldt and NIMS Postdoctoral Fellowships Editor-in-Chief of Sustainable Materials and Technologies (Elsevier) Principal Editor of Journal of Materials Research (MRS) Chair of the Energy Committee, The Minerals, Metals & Materials Society (TMS) Professor Sun has secured multiple ARC-funded research projects, including DP200103568 on 2D heterostructures and FT180100387 on bioinspired nanomaterials. He actively supervises research and collaborates internationally. His editorial leadership in high-impact journals underscores his influence in the global materials research community. He leads and participates in numerous international symposia and conferences, including TMS, MS&T, and ICACC, focusing on energy materials, carbon dioxide utilization, and responsive materials. His research group develops next-generation materials for sustainable applications, emphasizing scalability, performance, and environmental impact.

• Immunology
• Medical Microbiology
• Paediatrics and Reproductive Medicine
• +۳ مورد دیگر

Cecilia Johansson is a Professor of Mucosal Immunology at the National Heart & Lung Institute, part of the Faculty of Medicine at Imperial College London. Her academic journey includes undergraduate studies at Umeå and Lund Universities (Sweden), a PhD in Immunology from Lund University, and postdoctoral training at the NIH, USA. She leads a research group investigating immunity during viral infections, particularly focusing on type I interferons' role in lung inflammation and cancer interactions. Her affiliations include the Asthma UK Centre for Asthma and Allergy, the Immuno-Pathology Network, and the Imperial Network for Vaccine Research. She organizes the Imperial CREST Academy, fostering science education for students aged 16-18. Her work is supported by grants from MRC, BBSRC, Wellcome Trust, and others. Research interests span mucosal immunology, viral pathogenesis, T cell responses, and innate immunity. Her lab explores how viral infections influence lung cancer progression and develops vaccine strategies using lentiviral and AAV vectors. Recent studies highlight the interplay between neutrophils, cytokines, and viral outcomes in RSV and SARS-CoV-2 models.

Maximilian Reichertمشاهده پروفایل

استاد

• Cancer Biology
• Molecular Oncology
• Translational Medicine
• +۳ مورد دیگر

Prof. Maximilian Reichert is a Professor of Translational Pancreatic Cancer Research at the Technical University of Munich (TUM), leading the Department of Internal Medicine II (Gastroenterology) at Klinikum rechts der Isar. He also serves as Head of the Center for Translational Pancreatic Cancer Research and the Pancreatic Cancer Patient Organoid Core. His research focuses on epithelial plasticity in pancreatic cancer, organoid models, and personalized oncology. Dr. Reichert holds a Medical Doctorate (summa cum laude) from TUM and completed postdoctoral training at the University of Pennsylvania. His work spans clinical practice, translational research, and academic leadership. Key roles include Board Director of the Center of Organoid Systems/TUM (COS) and membership in the German Cancer Consortium (DKTK). Awards include UNCAN Expert (2023), Prix Forcheurs Jean-Marie Lehn (2017), and Max-Eder Junior Research Group Leader (2015). His lab investigates tumor metastasis, drug resistance, and innovative therapies, with over 100 peer-reviewed publications. Collaborations include projects on organoid-based diagnostics and CRISPR genome engineering. Education: Medical Degree (2008), Technical University of Munich Doctorate (2009), TUM Postdoc (2008–2013), University of Pennsylvania Research interests emphasize pancreatic cancer biology, with a focus on organoid models to predict treatment responses and study metastasis. His team has pioneered methods for isolating pancreatic ductal cells and developing 3D culture systems. Current projects include the UNITEPANC trial evaluating adjuvant therapies using organoids. Scientific contributions include defining Prrx1-driven mesenchymal plasticity in cancer progression and identifying vulnerabilities via epigenetic drug screening. Awards highlight his impact in oncology and translational research.

• Biophysics
• Nanotechnology
• Soft Matter Physics
• +۶ مورد دیگر

Univ.Prof. Dr. José Luis Toca-Herrera is a distinguished Professor of Biophysics at the University of Natural Resources and Life Sciences Vienna (BOKU), where he serves as Head of the Institute of Biophysics within the Department of Natural Sciences and Sustainable Resources. With a career spanning over two decades in biophysics and nanotechnology, he has established himself as an international leader in the application of atomic force microscopy to biological systems. His research bridges physics, chemistry, and biology to investigate the mechanical properties of biological materials at micro- and nanoscales. Prof. Toca-Herrera's research focuses on colloidal and molecular interactions, mechanical properties of biological materials, cell-substrate and cell-cell interactions, and self-assembly interfacial phenomena. His work applies mathematical and physical models to life sciences, social sciences, and education. He specializes in spectroscopy, surface analytical techniques, soft matter physics, and scanning probe microscopy. His laboratory investigates how physical forces influence cellular behavior, particularly in cancer research, where mechanical properties serve as biomarkers for disease progression. His publication record demonstrates a consistent trajectory of high-impact research in biophysics, with recent work spanning cancer cell mechanics, protein-lipid interactions, environmental applications of nanotechnology, and interdisciplinary studies bridging physics with social sciences. His team regularly publishes in top journals across physics, biophysics, and materials science, with multiple cover features recognizing the significance of their work. Scientific Recognition: Multiple cover features in prestigious journals including Small, Microscopy Research and Technique, Biotechnology Journal, and Toxins Visiting professorships at AGH University of Science and Technology in Krakow, Poland Best poster awards at European Colloid and Interface Society conferences Major research grants including Marie Curie, Ramón y Cajal, and Wellcome Trust funding Prof. Toca-Herrera leads several major research projects including the Human ECM-based platform for anti-cancer drug testing (CARES), Hierarchical polymer niches for enhanced cell attachment, and Adaptations for fog and dew harvesting in cactus spines. His international collaborations span Europe, Asia, and the Americas, with presentations delivered in over 15 countries. His laboratory combines atomic force microscopy with other biophysical techniques to create a comprehensive understanding of biomaterials at multiple scales. His research group operates within BOKU's advanced facilities for biophysics and nanotechnology, contributing significantly to the university's research profile in sustainable resource management and life sciences. The team's work has important implications for cancer diagnostics, drug delivery systems, and environmental applications of nanotechnology.